Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet (London, England)（2023）
摘要
Bristol Myers Squibb and Ono Pharmaceutical.
更多查看译文
关键词
nephrectomy,renal cell carcinoma,adjuvant nivolumab,ipilimumab,double-blind
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要